Cutaneous Immunofluorescence Antibodies, IgA, Serum
Use
The test is useful for confirming the presence of IgA antibodies to diagnose conditions such as pemphigoid, pemphigus, epidermolysis bullosa acquisita, or bullous lupus erythematosus. These are autoimmune blistering diseases where the detection of IgA antibodies against basement membrane zone or cell surface can provide a diagnostic tool alongside clinical and histological data.
Special Instructions
Specimens should be centrifuged and aliquoted into a plastic vial. It's crucial to ensure proper specimen handling to prevent diagnostic errors.
Limitations
The presence of low titer (< or =1:80) anti-cell surface antibodies alone should not be used to diagnose pemphigus without supportive histologic or direct IF studies. Results should be considered in conjunction with clinical information and other diagnostic tests due to variability in antibody presence across different stages and types of blistering diseases.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
LOINC Codes
- 104828-9
- 104829-7
- 104830-5
- 104833-9
- 104834-7
- 48767-8
Result Turnaround Time
2-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 30 days |